Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q4 2019 · 10-K
Revenue$100.45M$100.45M−13.4% vs Q4 2018 Net Income$33.13M$33.13M+27.9% vs Q4 2018 EPS Diluted$0.62$0.62+29.2% vs Q4 2018 Operating Income$40,816,000+2.4% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$41,762,000+27.5% Margins · derivedOperating margin40.6%+6.3 pt vs Q4 2018
Net margin33.0%+10.6 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 28, 2020 · 59 d after period end